Literature DB >> 6291495

Inclusion body myositis. A corticosteroid-resistant idiopathic inflammatory myopathy.

M J Danon, M G Reyes, O H Perurena, J C Masdeu, J R Manaligod.   

Abstract

In seven patients with slowly progressive muscle weakness, inclusion body myositis (IBM) was diagnosed on biopsy. None had stigmata of collagen-vascular disease or malignancy. Serum creatine kinase levels were mildly or moderately increased. The six patients treated with prednisone did not improve. Needle electromyography showed a "myopathic" pattern in all patients, but four also had diffuse neurogenic changes with normal nerve conductions. Histologic study of muscle showed a mixture of small rounded fibers varying in size, atrophic angulated fibers forming small groups, and hypertrophic fibers. Variable amounts of inflammation, necrosis, and regeneration were seen in all specimens. All showed numerous intracytoplasmic vacuoles lined with purple-blue granules. Electron microscopy showed membranous whorls and masses of abnormal filaments measuring 14 to 18 nm in diameter. Although IBM seems to be a distinct type of inflammatory myopathy, its etiology and pathogenesis are not clear.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6291495     DOI: 10.1001/archneur.1982.00510240022006

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  11 in total

1.  Inclusion Body Myositis.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-01       Impact factor: 3.598

2.  Mitochondrial abnormalities and peripheral neuropathy in inflammatory myopathy, especially inclusion body myositis.

Authors:  J M Schröder; M Molnar
Journal:  Mol Cell Biochem       Date:  1997-09       Impact factor: 3.396

3.  Inclusion body myositis: a case with associated collagen vascular disease responding to treatment.

Authors:  R J Lane; J J Fulthorpe; P Hudgson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-03       Impact factor: 10.154

4.  [PM-Scl antibody positive systemic sclerosis associated with inclusion-body myositis].

Authors:  S Kim; E Genth; T Krieg; N Hunzelmann
Journal:  Z Rheumatol       Date:  2005-10       Impact factor: 1.372

5.  The role of quantitative electromyography in inclusion body myositis.

Authors:  T H Brannagan; A P Hays; D J Lange; W Trojaborg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-12       Impact factor: 10.154

6.  Intranuclear inclusions in muscle, nervous tissue, and adrenal gland.

Authors:  J Tateishi; H Nagara; M Ohta; T Matsumoto; H Fukunaga; K Shida
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

7.  Inclusion body myositis with abundant ring fibers.

Authors:  M R Del Bigio; V Jay
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

8.  Inclusion body myositis: an underdiagnosed condition?

Authors:  N D Hopkinson; C Hunt; R J Powell; J Lowe
Journal:  Ann Rheum Dis       Date:  1993-02       Impact factor: 19.103

9.  Inclusion body myositis: clinical and histopathological features of 36 patients.

Authors:  S Beyenburg; S Zierz; F Jerusalem
Journal:  Clin Investig       Date:  1993-05

10.  Dysphagia in inclusion body myositis.

Authors:  A R Wintzen; G T Bots; H M de Bakker; J H Hulshof; G W Padberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-12       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.